Trigeminal neuralgia is pain that does not distinguish between day and night. The reason why it hurts more at night than during the day may be that the environment is quieter at night and the patient’s ability to perceive it is a little more intense, probably due to sympathetic excitement at night. However, this condition is not a symptom that most patients will have, and the exact pain level is not much related to the weather, environment, etc. Trigeminal neuralgia is a recurrent, transient paroxysmal pain in the trigeminal nerve innervation area, which is electric shock-like, knife-like and tearing-like pain, with sudden onset and stop. Each episode lasts from a few seconds to tens of seconds, with intervals of complete normalcy. The attacks are often triggered by random facial movements such as talking, chewing, brushing teeth and washing face, or by touching a certain area of the face (such as the upper lip, nose, supraorbital orifice, infraorbital orifice and oral gums), and these sensitive areas are called “trigger points”. To avoid attacks, patients are often afraid to eat or wash their faces, and their faces are haggard and emotional. The population prevalence is 182 per 100,000, with an annual incidence of 3 to 5 per 100,000, mostly in adults and the elderly, with the age of onset ranging from 28 to 89 years old, and 70% to 80% of cases occurring above the age of 40, with a peak age of 48 to 59. According to the latest survey data, it is becoming younger and the prevalence is increasing, which seriously affects the quality of life, work and social life of patients. Drug therapy for trigeminal neuralgia: Drug therapy is effective for trigeminal neuralgia and is especially suitable for treating patients with first occurrence of primary neuralgia. The efficacy of carbamazepine treatment is exact, and gabapentin, can be considered for the adjunctive treatment of primary. Although the efficacy of carbamazepine is superior to that of oxcarbazepine, the latter has somewhat fewer safety concerns. If any of the above sodium channel blockers are ineffective, surgical treatment should be considered as a next step. Spontaneous recovery of a typical primary is almost impossible, and the effect of drug therapy may alternate between partial remission, complete remission and relapse. Surgical treatment may be considered early when the efficacy of pharmacologic treatment has waned or when pharmacologic treatment has failed due to the development of drug side effects that are intolerable to the patient. Surgical treatment is more effective: there are various surgical procedures, including percutaneous radiofrequency temperature-controlled thermocoagulation of the trigeminal hemianopia, gamma knife treatment and microvascular decompression surgery. Among them, microvascular decompression is the most effective treatment and the longest duration of remission, especially for primary cases where drug therapy is ineffective. It should be noted that the surgical efficacy and complication rate of microvascular decompression surgery are closely related to the complexity of the disease and the operating level of the surgeon, and the incidence of surgical complications in some large hospitals is much lower than this value.